We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Won’t Predetermine Copaxone ANDA Requirements
FDA Won’t Predetermine Copaxone ANDA Requirements
January 2, 2013
The FDA has once again denied a Teva citizen petition that asks the agency to impose specific conditions on generic versions of multiple sclerosis treatment Copaxone.